Title |
-
Recommended Management of Hypertensive Patients with Diabetes for Renin-Angiotensin System (RAS) Inhibitors
|
Creator |
|
Rights |
-
© 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
Subject |
-
Other
Hypertension
-
Other
Diabetes Mellitus
-
Other
Renin-Angiotensin System (RAS) Inhibitors
-
Other
Angiotensin-Converting Enzyme (ACE) Inhibitors
-
Other
Angiotensin Receptor Blockers (ARB)
|
Description |
-
Other
Currently, major categories of antihypertensive agents include diuretics, beta-blockers, calcium channel blockers (CCBs), renin-angiotensin system (RAS) inhibitors [angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB)]. Among them, RAS (ACE inhibitors and ARB) would be recommended to be a first-line treatment when providing antihypertensive agents for hypertensive patients with diabetes, cardiovascular disease, and impaired renal function. Randomized controlled trials (RCT) of RAS inhibitors compared with other antihypertensive showed a rather lower relative risk (RR). They are all-cause death (RR - 0.95), cardiovascular death (RR - 0.84), incidence of cardiovascular disease (RR - 0.93), and incidence of renal dysfunction (RR - 0.91).
|
Publisher |
Asploro
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
VoR |
Identifier |
URI
http://repo.lib.tokushima-u.ac.jp/114836
|
Relation |
-
isIdenticalTo
DOI
https://doi.org/10.36502/2020/droa.6161
|
Journal |
-
Diabetes Research : Open Access
-
Volume Number2
Issue Number1
Page Start4
Page End8
|
File |
|
Oaidate |
2023-06-26 |